Hindustan Agrigenetics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 18, 2025, 8:37 am

Quick Insight

Hindustan Agrigenetics Ltd's current market dynamics reveal a concerning disparity between its intrinsic value and share price, with a P/E ratio of 740 suggesting overvaluation. The company's low ROE and ROCE at 3.61% and 3.53% respectively, along with a negative operating profit margin of -250.00%, raise red flags regarding its operational efficiency and profitability. Additionally, an ICR of -23.78x points towards potential liquidity issues. With a high percentage of public shareholders at 81.89%, there may be limited control by promoters. Investors should approach with caution, considering the company's weak financial performance and high valuation multiples.

Competitors of Hindustan Agrigenetics Ltd

All Competitor Stocks of Hindustan Agrigenetics Ltd

Quarterly Result

Last Updated: August 19, 2025, 1:50 pm

Below is a detailed analysis of the quarterly data for Hindustan Agrigenetics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 0.04 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.04 Cr..
• For Expenses, as of Jun 2025, the value is 0.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.69 Cr. (Mar 2025) to 0.14 Cr., marking a decrease of 0.55 Cr..
• For Operating Profit, as of Jun 2025, the value is -0.10 Cr.. The value appears strong and on an upward trend. It has increased from -0.69 Cr. (Mar 2025) to -0.10 Cr., marking an increase of 0.59 Cr..
• For OPM %, as of Jun 2025, the value is -250.00%. The value appears to be declining and may need further review. It has decreased from 0.00% (Mar 2025) to -250.00%, marking a decrease of 250.00%.
• For Other Income, as of Jun 2025, the value is 0.51 Cr.. The value appears strong and on an upward trend. It has increased from 0.18 Cr. (Mar 2025) to 0.51 Cr., marking an increase of 0.33 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
• For Net Profit, as of Jun 2025, the value is 0.40 Cr.. The value appears strong and on an upward trend. It has increased from -0.52 Cr. (Mar 2025) to 0.40 Cr., marking an increase of 0.92 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.00. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 12:57 pm

Balance Sheet

Last Updated: September 10, 2025, 3:52 pm

Below is a detailed analysis of the balance sheet data for Hindustan Agrigenetics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 4.40 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.40 Cr..
• For Reserves, as of Mar 2025, the value is 7.62 Cr.. The value appears to be declining and may need further review. It has decreased from 7.93 Cr. (Mar 2024) to 7.62 Cr., marking a decrease of 0.31 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 0.38 Cr.. The value appears to be improving (decreasing). It has decreased from 0.42 Cr. (Mar 2024) to 0.38 Cr., marking a decrease of 0.04 Cr..
• For Total Liabilities, as of Mar 2025, the value is 12.40 Cr.. The value appears to be improving (decreasing). It has decreased from 12.75 Cr. (Mar 2024) to 12.40 Cr., marking a decrease of 0.35 Cr..
• For Fixed Assets, as of Mar 2025, the value is 0.16 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Mar 2024) to 0.16 Cr., marking a decrease of 0.03 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 3.64 Cr.. The value appears strong and on an upward trend. It has increased from 1.97 Cr. (Mar 2024) to 3.64 Cr., marking an increase of 1.67 Cr..
• For Other Assets, as of Mar 2025, the value is 8.60 Cr.. The value appears to be declining and may need further review. It has decreased from 10.59 Cr. (Mar 2024) to 8.60 Cr., marking a decrease of 1.99 Cr..
• For Total Assets, as of Mar 2025, the value is 12.40 Cr.. The value appears to be declining and may need further review. It has decreased from 12.75 Cr. (Mar 2024) to 12.40 Cr., marking a decrease of 0.35 Cr..

Notably, the Reserves (7.62 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Hindustan Agrigenetics Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
• For Diluted EPS (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 5. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
• For Cash EPS (Rs.), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.15 (Mar 24) to -0.61, marking a decrease of 1.76.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 27.65 (Mar 24) to 27.32, marking a decrease of 0.33.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 27.32. It has decreased from 28.02 (Mar 24) to 27.32, marking a decrease of 0.70.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.17. It has decreased from 2.35 (Mar 24) to 0.17, marking a decrease of 2.18.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -0.59. This value is below the healthy minimum of 2. It has decreased from 1.46 (Mar 24) to -0.59, marking a decrease of 2.05.
• For PBIT / Share (Rs.), as of Mar 25, the value is -0.68. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.68, marking a decrease of 2.06.
• For PBT / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 0. It has decreased from 1.38 (Mar 24) to -0.69, marking a decrease of 2.07.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -0.69. This value is below the healthy minimum of 2. It has decreased from 1.07 (Mar 24) to -0.69, marking a decrease of 1.76.
• For PBDIT Margin (%), as of Mar 25, the value is -342.41. This value is below the healthy minimum of 10. It has decreased from 62.20 (Mar 24) to -342.41, marking a decrease of 404.61.
• For PBIT Margin (%), as of Mar 25, the value is -388.97. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -388.97, marking a decrease of 447.61.
• For PBT Margin (%), as of Mar 25, the value is -399.09. This value is below the healthy minimum of 10. It has decreased from 58.64 (Mar 24) to -399.09, marking a decrease of 457.73.
• For Net Profit Margin (%), as of Mar 25, the value is -395.59. This value is below the healthy minimum of 5. It has decreased from 45.44 (Mar 24) to -395.59, marking a decrease of 441.03.
• For Return on Networth / Equity (%), as of Mar 25, the value is -2.53. This value is below the healthy minimum of 15. It has decreased from 3.85 (Mar 24) to -2.53, marking a decrease of 6.38.
• For Return on Capital Employeed (%), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 10. It has decreased from 4.91 (Mar 24) to -2.42, marking a decrease of 7.33.
• For Return On Assets (%), as of Mar 25, the value is -2.45. This value is below the healthy minimum of 5. It has decreased from 3.68 (Mar 24) to -2.45, marking a decrease of 6.13.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 3. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
• For Quick Ratio (X), as of Mar 25, the value is 330.73. This value exceeds the healthy maximum of 2. It has increased from 27.72 (Mar 24) to 330.73, marking an increase of 303.01.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -23.78. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -23.78, marking a decrease of 23.78.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -26.77. This value is below the healthy minimum of 3. It has decreased from 0.00 (Mar 24) to -26.77, marking a decrease of 26.77.
• For Enterprise Value (Cr.), as of Mar 25, the value is 24.41. It has increased from 13.01 (Mar 24) to 24.41, marking an increase of 11.40.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 316.56. This value exceeds the healthy maximum of 3. It has increased from 12.59 (Mar 24) to 316.56, marking an increase of 303.97.
• For EV / EBITDA (X), as of Mar 25, the value is -92.45. This value is below the healthy minimum of 5. It has decreased from 20.24 (Mar 24) to -92.45, marking a decrease of 112.69.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 383.23. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.23, marking an increase of 361.46.
• For Price / BV (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has increased from 1.85 (Mar 24) to 2.46, marking an increase of 0.61.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 383.71. This value exceeds the healthy maximum of 3. It has increased from 21.77 (Mar 24) to 383.71, marking an increase of 361.94.
• For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Strength and Weakness